There is growing interest in the role of the oxytocin system in social cognition and behavior. Peripheral oxytocin concentrations are regularly used to approximate central concentrations in psychiatric research, however, the validity of this approach is unclear. Here we conducted a pre-registered systematic search and meta-analysis of correlations between central and peripheral oxytocin concentrations. A search of databases yielded 17 eligible studies, resulting in a total sample size of 516 participants and subjects. Overall, a positive association between central and peripheral oxytocin concentrations was revealed [r = 0.29, 95% CI (0.14, 0.42), p < 0.0001]. This association was moderated by experimental context [Q b (4), p = 0.003]. While no association was observed under basal conditions (r = 0.08, p = 0.31), significant associations were observed after intranasal oxytocin administration (r = 0.66, p < 0.0001), and after experimentally induced stress (r = 0.49, p = 0.001). These results indicate a coordination of central and peripheral oxytocin release after stress and after intranasal administration. Although popular, the approach of using peripheral oxytocin levels to approximate central levels under basal conditions is not supported by the present results.
Introduction
Oxytocin is a nine amino acid neuropeptide that acts on the widely distributed G-protein coupled oxytocin receptor in humans and almost all other vertebrate species (Horn and Swanson, 2013) . Oxytocin is released both into the central nervous system (CNS) and peripheral circulation from neurosecretory cells in the paraventricular (PVN) and supraoptical (SON) nuclei of the hypothalamus, where most endogenous oxytocin is synthesized. Central and peripheral compartments of the oxytocin system are separated anatomically by the blood-brain barrier, that only in exceptional cases is appreciably permeated by oxytocin (Neumann and Landgraf, 2012) .
Through central action, oxytocin is critically involved in a range of social behaviors and social cognitive functions (Guastella and MacLeod, 2012) . Endogenous oxytocin levels appear to co-vary with social cognitive function at all levels of information processing in humans and other mammals, with similar observed effects after administration of exogenous oxytocin (Bartz et al., 2011) . Growing clinical interest has focused on neurodevelopmental and psychiatric conditions characterized by social cognition and behavioral impairments, such as autism spectrum disorder (ASD) (Alvares et al., 2016b; Guastella and Hickie, 2016) and schizophrenia (Shilling and Feifel, 2016) , with the hope to explore the potential of oxytocin as a biomarker of these conditions, better understand their potential etiological pathways, and ultimately to ameliorate the associated social-cognitive and behavioral symptoms.
Several methodological approaches have been adopted to the study of oxytocin involvement in normal and impaired social behavior and cognition. These include the measurement of psychological or neurobiological outcomes after administration of exogenous oxytocin, and the assessment of endogenous oxytocin concentration covariance with psychological phenotypes and psychiatric disorder status. While crucial to the latter, concentrations of oxytocin have been sampled within both of these research traditions. Although the social cognitive effects of oxytocin are attributed to central mechanisms, oxytocin concentrations have typically, but not universally, been sampled in peripheral fluids such as blood plasma, saliva, and urine (McCullough et al., 2013 central bioavailability of the neuropeptide has been a crucial assumption in research where peripheral oxytocin concentrations are correlated with psychological phenotypes or psychiatric disorder status.
Although some animal research indicates that central release from the hypothalamus and peripheral release via the posterior pituitary is coordinated (Landgraf et al., 1988; Ross et al., 2009; Wotjak et al., 1998) , other research does not support this (Amico et al., 1990; Robinson and Jones, 1982) . Research is also mixed in humans, with some results consistent with related levels of central and peripheral endogenous oxytocin (Carson et al., 2014) , while others report no significant associations (Kagerbauer et al., 2013) . After exogenous oxytocin delivered via intranasal administration in humans, one study found a significant association between cerebrospinal fluid (CSF) and blood plasma concentrations of oxytocin (Wang et al., 2013) , while another found no significant association (Striepens et al., 2013) . Using peripheral oxytocin concentrations to index central concentrations is clearly appealing, given the more invasive procedures required to collect centrally circulating fluids in humans. However, it is currently unclear whether and when peripheral oxytocin measures can be used to index CNS concentrations and central oxytocin bioavailability.
The present systematic review and meta-analysis synthesized studies in which central and peripheral measures of oxytocin were simultaneously sampled into a summary effect size. The strength of the summary effect size is indicative of the plausibility of peripheral oxytocin as an index for central oxytocin concentrations. As eligible studies were likely to vary in a range of contextual specifications, several potential moderator variables were considered, including experimental paradigm, oxytocin sampling location, subject species, biochemical analysis methods, year of publication, and study quality. Such differences between contexts may contribute to variance in the correlations between central and peripheral oxytocin. Thus, it is possible that peripheral oxytocin can index central oxytocin concentrations in some contexts, but not others. Together, the purpose of this study was to examine whether, and under which circumstances, peripheral oxytocin is a correlate of central oxytocin concentrations.
Materials and methods
The systematic search and meta-analysis was conducted in accordance with the PRISMA guidelines (Moher et al., 2009) (Supplementary  Table S1 ) and recent recommendations for conducting correlational meta-analyses (Quintana, 2015) . Prior to the execution of the systematic search and meta-analysis, the protocol for this systematic review and meta-analysis was published (Valstad et al., 2016) and pre-registered on the PROSPERO registry (CRD42015027864).
Systematic literature search and inclusion of eligible studies
A systematic literature search was performed in two iterations to retrieve studies in which oxytocin had been simultaneously sampled in fluids or tissues located in central (e.g., local extracellular fluid or CSF) or peripheral (e.g. blood plasma or saliva) regions of the body. In the first iteration, a search was performed, using Ovid, in Embase and Medline with the following combination of terms: (oxytocin) AND (concentration* OR level*) AND (plasma OR blood OR saliva* OR urin*) AND (central OR csf OR "cerebrospinal fluid"). The following constraints were applied to limit search results: the result should be (i) a full-text article or a conference abstract, (ii) written in English, that was (iii) published after 1971, when biochemical analysis of oxytocin content using enzyme immunoassay was made commercially available. Searches were conducted on April 1, 2016 and August 2, 2016, and resulted in a total of 572 studies. Out of these, 110 were relevant. A second iteration was performed in which citing articles and reference lists of included studies were examined for remaining relevant studies (Fig. 1 ). After retrieval, relevant studies were screened for inclusion based on the criterion that effect sizes for the correlation between central and peripheral concentrations of oxytocin must be obtainable. While 110 of the studies retrieved in the systematic search were relevant, only 17 of these satisfied this criterion.
Data extraction and management
Effect sizes and sample sizes were extracted from eligible studies. For some articles, effect sizes were stated explicitly, or directly obtainable through tables of individual values. In other articles, individual values were represented in graphs such as scatterplots, in which case a web plot digitizer (Rohatgi, 2015) was used for conversion of plots into numerical values. Since some articles contained both a scatterplot and a directly stated effect size, this plot digitizer was validated through comparing effect sizes provided by authors with plot digitizer outputs, revealing almost perfect precision (Supplementary text S2). Some articles did not provide relevant effect sizes, individual values in tables, or scatterplots. Since 15 years is a common time frame for the retention of clinical data, authors of such articles published from 2001 were contacted and asked to provide effect sizes. Articles lacking this information that were published before 2001 (n = 68), and studies performed by authors that were not able to respond to the data request (n = 25), were not included in the meta-analysis. Data were extracted from all eligible studies using a custom data extraction form (Supplementary Table S3 ).
Statistical analysis
Statistical analysis was performed with R statistical software version 3.2.4. (R Core Team, 2016) , using the MAc (Del Re and Hoyt, 2012), metafor (Viechtbauer, 2010) , and multcomp (Hothorn et al., 2008 ) R packages. The dataset and script to perform the analyses are available at https://osf.io/aj55y/ Prior to meta-analytic synthesis, raw effect sizes were transformed to Fisher's z for variance stabilization (Borenstein et al., 2009) . Raw effect sizes given as Spearman's ρ were first transformed to Pearson's r according to Gilpin (1993) , and then transformed to Fisher's z for metaanalysis. For studies reporting several effect sizes, or reporting one effect size based on repeated measures, within-study variance was estimated using a procedure described in the Supplementary text S4. A random effects model (DerSimonian and Kacker, 2007) , where between-studies variance (τ 2 ) was estimated using a restricted maximum likelihood method, was used in the synthesis of individual effect sizes into a summary effect size. Outlier diagnostics were also performed to identify potential effect size outliers (Viechtbauer, 2010) . Point estimates were converted back to Pearson's r for interpretive purposes. The observed variance between studies may be due to heterogeneity (variance in the true effect sizes between studies) and within-study variance. Q, the significance of Q, and I 2 were computed in order to examine variance and heterogeneity among effect sizes of included studies. I 2 values of ∼25%, ∼50%, and ∼75% were interpreted as low, moderate, and high, respectively (Higgins et al., 2003) . Potential moderator variables were defined a priori (Valstad et al., 2016) . Some of the levels for moderator variables were also defined a priori, such as the levels baseline condition (lack of experimental intervention) and intranasal administration for the experimental paradigm moderator. Other levels of moderator variables were adjusted from pre-planned analyses post hoc based on the specific characteristics of included studies (for details, see Supplementary text S5). Due to the ambiguity of the concept "baseline", an inclusive and a strict definition was adopted for sensitivity analysis, where the former was defined as lack of experimental manipulation, while the latter was defined as lack of experimental manipulation together with lack of specific context (e.g. lactation). For one of the studies (Striepens et al., 2013) effect sizes for the intranasal oxytocin (n = 11) and baseline (n = 4) conditions were not possible to disentangle, and the combined effect size was categorized in the intranasal subgroup. A sensitivity analysis for the moderator experimental paradigm was performed in which this study was removed. In all the included studies, peripheral oxytocin was sampled from blood, such that no moderator analysis for peripheral sample type was required. For most human participants (n ≥ 212), central oxytocin was collected from the CSF by spinal puncture. A random effects model with separate estimates of between study variance was applied for all categorical moderator variables, yielding summary weighted mean effects and the significance of subgroup effects, which were calculated for each subgroup. Although mammals share essential oxytocin system characteristics, such as production of oxytocin in the hypothalamus, peripheral and central release of oxytocin from hypothalamus, and a blood brain barrier that inhibits diffusion of oxytocin between the CNS and systemic circulation (Horn and Swanson, 2013) , the between-species differences (Valstad et al., 2016) necessitated an additional analysis to examine the role of species in the different effects observed between experimental paradigms. When there were more than two subgroups, pairwise comparisons were performed between all moderator categories with Holm-adjusted p-values to control the family-wise error rate. Meta-regression models were fitted to account for heterogeneity of continuous moderator variables.
Data quality measures
Small study bias, which includes both publication bias and study quality bias (Egger et al., 1997; Schulz et al., 1995) , was assessed by visually inspecting a funnel plot and performing Egger's regression test Egger et al., 1997) . A significant test (p < 0.05) is indicative of small study bias. A contour enhanced funnel plot, which superimposes key areas of statistical significance (p = 0.1, p = 0.05, p = 0.01), was constructed to specifically assess for risk of publication bias (Peters et al., 2008 ). An over-representation of effect sizes in the key areas of significance is indicative of publication bias risk. Since the decision to report a specific effect size, in contrast to the decision to publish a study, is not directly dependent on sample size, the regression test for funnel plot asymmetry does not rule out the possibility that there could be a bias in the type of evidence that is reported in published studies. To examine whether this was a source of bias in the set of included studies, the included studies that explicitly stated effect sizes were compared to the studies where effect sizes were obtained by other means, such as data scraping or author request. Furthermore, studies that reported the relevant effect size explicitly were separately examined for publication bias in order to test the possibility for publication bias among studies where the correlation between central and peripheral oxytocin was a research focus (i.e., focal studies).
There may also be issues with validity of the data that are internal to included studies. A custom risk of bias tool (Supplementary Table S6) was used (by ME and AMM) to systematically assess within-study risk of bias in included studies. This tool was developed by adapting the tool used in another meta-analysis (Alvares et al., 2016a) to the context of oxytocin research.
Results
17 studies yielding 32 effect sizes were included in the metaanalysis (Table 1 ; Fig. 1 ; Striepens et al., 2013; Carson et al., 2014; Martin et al., 2014 , Kagerbauer et al., 2013 Neumann et al., 2013 , Wang et al., 2013 Kojima et al., 2012; Williams et al., 2012; Sansone et al., 2002; Amico et al., 1990; Takeda et al., 1985; Takagi et al., 1985; Jokinen et al., 2012; Jin et al., 2007; Keverne and Kendrick, 1991; Engelmann et al., 2004; Kleindienst et al., 2004) . The total number of participants/subjects across studies was 504. Among these, 256 were human, 237 were rodents, 7 were sheep, and 4 subjects were nonhuman primates.
Association between central and peripheral concentrations of oxytocin
There was a positive correlation between central and peripheral concentrations of oxytocin [r = 0.29, 95% CI (0.14, 0.42), p < 0.0001; Fig. 2 ]. Egger's regression test revealed no overall M. Valstad et al. Neuroscience and Biobehavioral Reviews 78 (2017) 117-124 evidence of small study bias (p = 0.33; Fig. 3A) , and no evidence for small study bias among focal studies (p = 0.24). There was no significant difference between studies that reported [r = 0.35, 95% CI (0.18, 0.50)], and studies that did not explicitly report the relevant effect size [r = 0.15, 95% CI (-0.10, 0.38)]. An inspection of the contour enhanced funnel plot did not reveal an over-representation of effect sizes in the significance contours (Fig. 3B) , indicating a low risk of publication bias. Furthermore, a meta-regression revealed that risk of bias did not influence effect sizes (p = 0.24; Fig. 3C ). Influence diagnostics identified one potential outlier (Wang et al., 2013) . A sensitivity analysis, which involved re-analysis without the identified outlier, revealed a similar summary effect size as the original analysis that was also statistically significant [r = 0.23, 95% CI (0.11, 0.35), p = 0.0002]. As this sensitivity analysis suggested that this single effect size only had a modest effect on the overall meta-analysis, it was retained for the remainder of the analyses. In the total sample of included studies, there was a moderate-to-high level of heterogeneity [Q = 86.19, p < 0.0001, I 2 = 62.8% 95% CI (37%, 77%)]. Accordingly, moderator analyses were performed to identify sources of heterogeneity.
Impact of moderators on effect size
A moderator analysis revealed that part of the heterogeneity in the model was due to the type of experimental paradigm [Q b (4) = 16.03, p = 0.003; Fig. 4A ]. Across experimental paradigms, positive associations were observed for the intranasal oxytocin (IN-OT) condition (r = 0.66, p < 0.0001, k = 4) and after stress interventions (r = 0.49, p = 0.001, k = 5; Supplementary Table S7 ). The IN-OT association was reproduced (r = 0.75, p < 0.0001, k = 3) in a sensitivity analysis where one effect size (Striepens et al., 2013) was removed due to containing some samples (n = 4) from a baseline condition. In contrast, no association was observed in the baseline condition (r = 0.08, p = 0.31, k = 15). The subgroup effects for the peripheral oxytocin administration category (r = 0.29, p = 0.28, k = 3), as well as for the 'other' category (r = 0.30, p = 0.07, k = 5) were not significant. The results for the baseline condition were similar (r = 0.10, p = 0.27, k = 13) when applying a strict rather than inclusive extension of 'baseline'. An inspection of all possible pairwise comparisons with Holm corrected p-values revealed that the IN-OT point estimate was significantly greater than the baseline point estimate (p = 0.003; Fig. 4A ). While there were no other significant pairwise comparisons, the increased stress point estimate compared to baseline point estimate was on the border of statistical significance (p = 0.14). When constrained to human studies, results for the levels of the experimental paradigm moderator were reproduced [Q b (2) = 7.65, Analysis of the effect of central sampling location on effect sizes was on the border of significance [Q b (3) = 6.33, p = 0.10; Fig. 4B ], suggesting that specific brain sampling location differences may contribute to observed heterogeneity. Across levels of the central sampling location moderator, subgroup effects for hypothalamus (r = 0.42, p = 0.0004, k = 10), central amygdala (r = 0.52, p = 0.034, k = 3), and hippocampus (r = 0.50, p = 0.034, k = 3; Supplementary Table S7) were significant. The subgroup effect for samples taken from CSF (r = 0.14, p = 0.14, k = 16) was not significant. Pairwise comparisons did not reveal any significant difference between any of these subgroups.
The moderator analysis for species was not significant [Q b (3) = 1.87, p = 0.60; Fig. 4C ], suggesting that species diversity might not contribute to heterogeneity among effect sizes. Across levels of the species moderator, only the subgroup effect for rodents was significant (r = 0.35, p = 0.0004, k = 19; Supplementary Table S7 ). The point estimates for human (r = 0.22, p = 0.081, k = 10), sheep (r = 0.19, p = 0.55, k = 2), and non-human primate (r = −0.34, p = 0.53, k = 1) subgroups were not significant. There was no significant difference between any of the levels of this moderator variable. An exploratory mixed-effect meta-regression model was fitted to assess whether the influence of species type (human vs. rodent) on the correlation between central and peripheral levels varied between experimental paradigms (intranasal oxytocin vs. baseline vs. other). A Wald-type chi-square test did not reveal evidence for a significant interaction (Q m (2) = 0.48, p = 0.79).
The biochemical analysis method moderator analysis was not significant [Q b (2) = 4.45, p = 0.11; Fig. 4D ], indicating that this moderator variable is not likely to contribute to heterogeneity among effect sizes. Across the levels of the biochemical analysis method moderator variable, subgroup effects for both RIA (r = 0.28, p = 0.0005, k = 24) and EIA (r = 0.42, p = 0.0035, k = 6) were significant. There was no significant effect for LC/MS (r = −0.2, p = 0.43, k = 2) and no significant differences between the levels of this moderator variable. The peptide extraction moderator analysis was not significant [Q b (1) = 0.06, p = 0.80; Fig. 4E ]. Both with (r = 0.31, p = 0.0002, k = 24) and without (r = 0.35, p = 0.0278, k = 6) extraction subgroup effects were significant (Supplementary Table S7 ). Finally, the year of publication did not significantly moderate the relationship between central and peripheral oxytocin concentrations [Q (1) = 2.0, p = 0.15; Fig. 3D ].
Discussion
The present systematic meta-analysis revealed a positive correlation between concentrations of oxytocin in blood plasma and oxytocin concentrations in the CNS. However, the association was moderate and showed a high degree of heterogeneity, suggesting that the observed association might not be present across all contexts. Experimental paradigm was the moderator variable most likely to account for this heterogeneity. After IN-OT, as well as after an experimental stressor, there was a positive correlation between central and peripheral oxytocin concentrations. However, in the baseline condition, there was no evidence of correlation, neither for the entire sample of subjects, nor for any of the species analyzed separately. Notably, there was a statistically significant difference between the summary statistic for IN-OT studies and baseline studies. Given the lack of evidence for a correlation between peripheral and central oxytocin levels in the baseline condition, the data suggest blood plasma may not efficiently index central oxytocin concentrations under baseline conditions. Furthermore, this result provides additional indirect evidence for the effectiveness of the blood-brain barrier in restricting oxytocin diffusion between systemic circulation and the CNS (Neumann and Landgraf, 2012) , as well supporting the hypothesis that under baseline conditions, hypothalamic oxytocin release into blood and into the CNS is uncoordinated (Amico et al., 1990) .
There is a substantial body of research attempting to link peripheral oxytocin concentrations with psychological phenotypes or psychiatric disorder status. Since the social-cognitive effects of oxytocin have been assumed to arise from oxytocin action in the CNS, the assumption that peripheral and central oxytocin concentrations correlate in a baseline condition was crucial in the interpretation of the results from these two approaches (e.g. Hoge et al., 2008; Rubin et al., 2010) . This assumption is called into question by the present data. These results may have two possible, mutually exclusive, implications for the interpretation of studies within these research traditions: either the apparent social cognitive effects are type I errors produced by chance, or the demonstrated covariance between social cognition and endogenous oxytocin in systemic circulation arise from some phenomenon unrelated to central oxytocin levels. The former potential interpretation is consistent with the evidence of publication bias that has surfaced in the field of psychological and psychiatric oxytocin research (Lane et al., 2016; McCullough et al., 2013; Walum et al., 2016) . Likewise, in a recent meta-analysis, basal levels of neither CSF nor plasma oxytocin were associated with psychiatric disorder status, with the exception of anorexia nervosa, which was associated with a reduction in plasma oxytocin levels (Rutigliano et al., 2016) . The latter interpretation points to a potential peripheral mechanism for the observed social cognitive correlates of basal peripheral oxytocin concentrations. One potential causal mechanism is oxytocin action on peripheral tissues that provide afferent feedback to the CNS (Horn and Swanson, 2013) .
In contrast to what was discovered under baseline conditions, this meta-analysis revealed a positive correlation between central and peripheral oxytocin after intranasal administration of oxytocin, both overall and when analysis was limited to studies in humans. Almost every study examining the effects of exogenous oxytocin on social cognition and behavior in normal and clinical populations have made use of the intranasal delivery route (Andari et al., 2010; Domes et al., 2007; Guastella et al., 2008; Kosfeld et al., 2005) . The motivation behind administering oxytocin intranasally is to obtain non-invasive delivery of oxytocin into the brain. Although vasopressin, which is structurally similar to oxytocin, has been shown to enter the CSF after intranasal administration (Born et al., 2002) , and intranasal oxytocin has been shown to enter the CSF in non-human primates (Lee et al., 2017) it is not entirely clear where intranasally administered oxytocin travels in humans, or whether it actually reaches brain areas containing oxytocin receptors such as the hypothalamus or the amygdalae (Quintana et al., 2015a) . However, recent work in humans comparing intranasal and intravenous oxytocin administration indicates that despite comparable peripheral oxytocin concentrations after both administration routes, social cognitive (Quintana et al., 2015b) and neural effects were only observed after intranasal administration. Together, these results are consistent with a direct nose-to-brain transport of intranasally administered oxytocin via olfactory and trigeminal nerve fibers, although it is not clear whether the increased correlation after intranasal oxytocin administration stems from increased hypothalamic release of oxytocin, or simply from exogenous oxytocin reaching both CSF and peripheral circulation.
In this meta-analysis, a positive association was also found between central and peripheral concentrations of oxytocin after experimental stress induction. Stress induction involved either separation from a mother (Kojima et al., 2012) , or a forced swim test (Williams et al., 2012) . As the authors suggest (Williams et al., 2012) , the hypothalamus-pituitary-adrenal (HPA) axis and related hormones such as corticosterone interact with the oxytocin system to regulate stress responses. Such interaction may occur through interneurons between magnocellular and parvocellular neurons in the PVN (Ferguson et al., 2008) , from which oxytocin and corticotropin-releasing hormone are released. Furthermore, interaction may be mediated through corticosteroid effects on vasoconstriction and heart rate, which in turn could affect oxytocin release through baroreceptors and the vagal feedback system (Horn and Swanson, 2013; Quintana et al., 2015a) .
There are some limitations to the study worth mentioning. First, although a total of 17 studies were included in the main analysis, some moderator analysis subgroups contained few studies, an extreme instance of which is the amygdala and hippocampus levels of the central sampling location moderator, where the data from only one study are included. Relatedly, several subgroups contained few or no human studies. In cases such as the stress subgroup, with no human studies, or the intranasal oxytocin subgroup, with two human studies (Striepens et al., 2013; Wang et al., 2013) , generalization to humans is not straightforward and results should be considered preliminary. The effect size (Striepens et al., 2013) that was categorized to the intranasal subgroup despite representing a combination of intranasal (n = 11) and baseline (n = 4) samples may reduce the reliability of the correlation estimate for intranasal oxytocin in humans. Second, to estimate variances for effect sizes from repeated measures, dependent samples variance estimation was used to control for dependency between samples. Since exact dependencies between repeated samples were unknown, there is a chance that variances for effect sizes obtained in repeated measures designs were slightly overestimated or underestimated, relative to variances for effect sizes obtained in single sample designs. A differential variance estimation would favor one of the two study types with respect to the relative weight they were afforded in the main analysis. However, since there is no a priori reason to believe that study type should impact upon the estimated effect sizes, it is unlikely that this potential bias had any considerable effects on the results. Third, even if there was no evidence for publication bias, or for bias in report of effect sizes, there may be some bias in the subjects sampled for studies where CSF was collected. Across included studies, some of the human participants had medical conditions (Carson et al., 2014; Striepens et al., 2013; Wang et al., 2013) . Medical conditions are often associated with pain, and pain may influence oxytocin release: in one study, chemical pain stimulation increased oxytocin release within the brain, but not in plasma (Yang et al., 2007) . If pain leads to uncoordinated release, then this may bias the results of this metaanalysis in a negative direction. However, the strongest correlation between central and peripheral concentrations of oxytocin among included studies − which was also identified as a potential outlier − was observed in a sample of headache patients (Wang et al., 2013) . This may point to the opposite possibility that pain could bias the effect sizes of this meta-analysis in a positive direction. To ensure that this study did not inflate the effect size for the IN-OT condition, a secondary analysis was performed with this study removed, yielding comparable results.
The collection of peripheral oxytocin measures to index central levels has obvious appeal given the difficulties surrounding central collection. However, research has yet to establish whether this is a valid experimental approach. The results of this meta-analysis indicate that there is a positive association between central and peripheral concentrations of oxytocin, but this association depends on experimental context. There was evidence for a positive association between central and peripheral concentrations of oxytocin after intranasal oxytocin administration and after experimental stress induction. However, as there was no evidence for an association between central and peripheral oxytocin concentrations under baseline conditions, future studies on the role of basal oxytocin in cognition or social behavior should avoid using peripheral oxytocin measures to make inferences on central oxytocin concentrations. 
